An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
For the first time, physicians in the Emergency Department have evidence-based recommendations on how best to catch the life-threatening conditions that make some people faint.
Researchers have successfully developed two biomarkers that could help predict the risk of a heart condition and stroke.
Atrial fibrillation is the most common form of heart arrhythmia. About ten per cent of everyone over age 75 develop this condition, in which the two upper chambers of the heart (the atria) beat much faster than the main chambers (the ventricles), creating a fluttering feeling in the chest.
A group of researchers from the departments of Physical Therapy, Medicine and Electronic Engineering of Valencia University and from the innovations group ITACA have just published research into physical exercise as a protector against sudden cardiac death. The study has been published in the 'PlosOne' journal.
Continuous indoor exposure to second-hand tobacco smoke triggers changes in the heart's electrical activity, known as cardiac alternans, that can predict cardiac arrhythmia and sudden cardiac death, a new study from UC Davis Health researchers shows.
In 2015, then President Barack Obama launched a precision medicine initiative, saying that its promise was "delivering the right treatments, at the right time, every time to the right person.
Scientists have uncovered the first evidence to associate dietary salt intake with the risk of developing a common heart condition that affects millions of people worldwide, in a new study published in the Annals of Medicine.
For more than a decade, the latest Apple products have been the annual must-have holiday gift for the tech-savvy. That raises the question: Is the newest Apple Watch on your list — either to give or receive — this year?
Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its STELLAR U.S. Investigational Device Exemption study.
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Each year, at least 3 million people worldwide die of sudden cardiac death. In the U.S., this number reaches up to 450,000 people.
Augmented reality, a technology that superimposes computer-generated information on a user's view of the real world, offers a new platform to help physicians better visualize complex medical data, particularly before and during medical procedures.
Sudden cardiac death is a common cause of death in patients with congenital or acquired heart disease. An implanted cardiac defibrillator can effectively put a stop to any underlying cardiac arrhythmia.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
Checking the heartbeat of babies in the womb is set to become more accurate and less stressful for expectant mothers thanks to research by the University of Sussex.
An interview with Glyn Barnes, Marketing Director for AliveCor, about Kardia Mobile and the Kardia Band, the FDA approved devices which can provide a diagnostic quality ECG reading in 30 seconds.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Atrial fibrillation is the most common type of irregular heartbeat, or cardiac arrhythmia, affecting 2-3 % of the European population and as many as one in 10 people over the age of 80.